The controversy was addressed in an exhaustive analysis carried out by de Sauvage and co-workers [78] at Genentech Inc., using a more potent, and less toxic, SMO inhibitor termed HhAntag, in addition to cyclopamine, to investigate paracrine and autocrine HH pathway signalling in tumour cells. Here, SMO is linked to neoplasm.